Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review

Tae Jin Kim, Kang Su Cho, Kyo Chul Koo, Tae Jin Kim, Kang Su Cho, Kyo Chul Koo

Abstract

Advancements in the understanding of tumor immunology in urothelial carcinoma (UC) have led to U.S Food and Drug Administration (FDA) approval of five novel anti-programmed cell death protein-1/ligand 1 (PD-1/L1) checkpoint inhibitors. In 2017, the anti-PD-L1 antibody atezolizumab and the anti-PD-1 antibody pembrolizumab gained approval for use in cisplatin-ineligible patients with locally advanced and metastatic UC. These approvals were based on single-arm trials, IMvigor210 (atezolizumab) and KEYNOTE-052 (pembrolizumab). Since then, additional checkpoint inhibitors, including avelumab, durvalumab, and nivolumab, have gained approval. Preliminary results suggest additional benefits with combinations of these agents in both first- and subsequent-line therapies, inferring a paradigm shift in the future treatment approach in advanced UC. Ongoing clinical trials will investigate how to utilize predictive biomarkers for optimal patient selection and to incorporate immunotherapy into earlier lines of multimodal treatment. In this comprehensive review, we summarize the evidence supporting the use of checkpoint inhibitors for patients with UC, and highlight ongoing clinical trials that are investigating novel combinations of immunotherapy in various disease settings.

Keywords: biomarkers; clinical trials; immune checkpoint inhibitor; immunotherapy; urothelial carcinoma.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Siegel R., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7–30. doi: 10.3322/caac.21442.
    1. Chang S.S., Bochner B.H., Chou R., Dreicer R., Kamat A.M., Lerner S.P., Lotan Y., Meeks J.J., Michalski J.M., Morgan T.M., et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J. Urol. 2017;198:552–559. doi: 10.1016/j.juro.2017.04.086.
    1. Spiess P.E., Agarwal N., Bangs R., Boorjian S.A., Buyyounouski M.K., Clark P.E., Downs T.M., Efstathiou J.A., Flaig T.W., Friedlander T., et al. Bladder cancer, version 5. 2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2017;15:1240–1267. doi: 10.6004/jnccn.2017.0156.
    1. Rosenberg J.E., Hoffman-Censits J., Powles T., van der Heijden M.S., Balar A.V., Necchi A., Dawson N., O’Donnell P.H., Balmanoukian A., Loriot Y., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–1920. doi: 10.1016/S0140-6736(16)00561-4.
    1. Lopez-Beltran A., Henriques V., Montironi R., Cimadamore A., Raspollini M.R., Cheng L. Variants and new entities of bladder cancer. Histopathology. 2019;74:77–96. doi: 10.1111/his.13752.
    1. Moch H., Humphrey P.A., Ulbright T.M., Reuter V. WHO Classification of Tumours of the Urinary System and Male Genital Organs. International Agency for Research on Cancer; Lyon, France: 2016.
    1. Kim S.P., Frank I., Cheville J.C., Thompson R.H., Weight C.J., Thapa P., Boorjian S.A. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J. Urol. 2012;188:405–409. doi: 10.1016/j.juro.2012.04.020.
    1. Scosyrev E., Ely B.W., Messing E.M., Speights V.O., Grossman H.B., Wood D.P., de Vere White R.W., Vogelzang N.J., Trump D.L., Natale R.B., et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group- Directed Intergroup Study (S8710) BJU Int. 2011;108:693–699. doi: 10.1111/j.1464-410X.2011.10582.x.
    1. Tamas E.F., Nielsen M.E., Schoenberg M.P., Epstein J.I. Lymphoepithelioma-like carcinoma of the urinary tract: A clinicopathological study of 30 pure and mixed cases. Mod. Pathol. 2007;20:828–834. doi: 10.1038/modpathol.3800823.
    1. Lopez-Beltran A., Paner G., Blanca A., Montironi R., Tsuzuki T., Nagashima Y., Chuang S.S., Win K.T., Madruga L., Raspollini M.R., et al. Lymphoepithelioma-like carcinoma of the upper urinary tract. Virchows Arch. 2017;470:703–709. doi: 10.1007/s00428-017-2117-z.
    1. Robertson A.G., Kim J., Al-Ahmadie H., Bellmunt J., Guo G., Cherniack A.D., Hinoue T., Laird P.W., Hoadley K.A., Akbani R., et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017;171:540–556. doi: 10.1016/j.cell.2017.09.007.
    1. Roupret M., Babjuk M., Comperat E., Zigeuner R., Sylvester R.J., Burger M., Cowan N.C., Böhle A., Van Rhijn B.W., Kaasinen E., et al. European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur. Urol. 2015;68:868–879. doi: 10.1016/j.eururo.2015.06.044.
    1. Galsky M.D., Hahn N.M., Rosenberg J., Sonpavde G., Hutson T., Oh W.K., Dreicer R., Vogelzang N., Sternberg C.N., Bajorin D.F., et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J. Clin. Oncol. 2011;29:2432–2438. doi: 10.1200/JCO.2011.34.8433.
    1. Kaufman D., Raghavan D., Carducci M., Levine E.G., Murphy B., Aisner J., Kuzel T., Nicol S., Oh W., Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin. Oncol. 2000;18:1921–1927. doi: 10.1200/JCO.2000.18.9.1921.
    1. von der Maase H., Hansen S.W., Roberts J.T., Dogliotti L., Oliver T., Moore M.J., Bodrogi I., Albers P., Knuth A., Lippert C.M., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 2000;18:3068–3077. doi: 10.1200/JCO.2000.18.17.3068.
    1. McCaffrey J.A., Hilton S., Mazumdar M., Sadan S., Kelly W.K., Scher H.I., Bajorin D.F. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J. Clin. Oncol. 1997;15:1853–1857. doi: 10.1200/JCO.1997.15.5.1853.
    1. Sweeney C.J., Roth B.J., Kabbinavar F.F., Vaughn D.J., Arning M., Curiel R.E., Obasaju C.K., Wang Y., Nicol S.J., Kaufman D.S. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J. Clin. Oncol. 2006;24:3451–3457. doi: 10.1200/JCO.2005.03.6699.
    1. Sternberg C.N., Yagoda A., Scher H.I., Watson R.C., Geller N., Herr H.W., Morse M.J., Sogani P.C., Vaughan E.D., Bander N., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989;64:2448–2458. doi: 10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>;2-7.
    1. Loehrer P.J., Sr., Einhorn L.H., Elson P.J., Crawford E.D., Kuebler P., Tannock I., Raghavan D., Stuart-Harris R., Sarosdy M.F., Lowe B.A., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J. Clin. Oncol. 1992;10:1066–1073. doi: 10.1200/JCO.1992.10.7.1066.
    1. von der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., Moore M.J., Zimmermann A., Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 2005;23:4602–4608. doi: 10.1200/JCO.2005.07.757.
    1. Bellmunt J., von der Maase H., Mead G.M., Skoneczna I., De Santis M., Daugaard G., Boehle A., Chevreau C., Paz-Ares L., Laufman L.R., et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J. Clin. Oncol. 2012;30:1107–1113. doi: 10.1200/JCO.2011.38.6979.
    1. Dash A., Galsky M.D., Vickers A.J., Serio A.M., Koppie T.M., Dalbagni G., Bochner B.H. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107:506–513. doi: 10.1002/cncr.22031.
    1. De Santis M., Bellmunt J., Mead G., Kerst J.M., Leahy M., Maroto P., Gil T., Marreaud S., Daugaard G., Skoneczna I., et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/ carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J. Clin. Oncol. 2012;30:191–199. doi: 10.1200/JCO.2011.37.3571.
    1. Hainsworth J.D., Meluch A.A., Litchy S., Schnell F.M., Bearden J.D., Yost K., Greco F.A. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 2005;103:2298–2303. doi: 10.1002/cncr.21078.
    1. Hurwitz M.E., Sokhn J., Petrylak D.P. Cancer immunotherapy: New applications in urologic oncology. Curr. Opin. Urol. 2016;26:535–542. doi: 10.1097/MOU.0000000000000345.
    1. Donin N.M., Lenis A.T., Holden S., Drakaki A., Pantuck A., Belldegrun A., Chamie K. Immunotherapy for the treatment of urothelial carcinoma. J. Urol. 2017;197:14–22. doi: 10.1016/j.juro.2016.02.3005.
    1. Anderson A.C., Anderson D.E., Bregoli L., Hastings W.D., Kassam N., Lei C., Chandwaskar R., Karman J., Su E.W., Hirashima M., et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318:1141–1143. doi: 10.1126/science.1148536.
    1. Schepisi G., Brighi N., Cursano M.C., Gurioli G., Ravaglia G., Altavilla A., Burgio S.L., Testoni S., Menna C., Farolfi A., et al. Inflammatory biomarkers as predictors of response to immunotherapy in urological tumors. J. Oncol. 2019;11:e12. doi: 10.1155/2019/7317964.
    1. Sica G.L., Choi I.H., Zhu G., Tamada K., Wang S.D., Tamura H., Chapoval A.I., Flies D.B., Bajorath J., Chen L. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003;18:849–861. doi: 10.1016/S1074-7613(03)00152-3.
    1. Loos M., Hedderich D.M., Friess H., Kleeff J. B7-H3 and its role in antitumor immunity. Clin. Dev. Immunol. 2010;2010 doi: 10.1155/2010/683875.
    1. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., Skora A.D., Luber B.S., Azad N.S., Laheru D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015;372:2509–2520. doi: 10.1056/NEJMoa1500596.
    1. Kelderman S., Schumacher T.N., Kvistborg P. Mismatch repair-deficient cancers are targets for anti-PD-1 therapy. Cancer Cell. 2015;28:11–13. doi: 10.1016/j.ccell.2015.06.012.
    1. Singh P., Black P. Urologic Oncology: Seminars and Original Investigations. Volume 34. Elsevier; Amsterdam, The Netherlands: 2016. Emerging role of checkpoint inhibition in localized bladder cancer; pp. 548–555.
    1. Lawrence M.S., Stojanov P., Polak P., Kryukov G.V., Cibulskis K., Sivachenko A., Carter S.L., Stewart C., Mermel C.H., Roberts S.A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–218. doi: 10.1038/nature12213.
    1. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Børresen-Dale A.L., et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421. doi: 10.1038/nature12477.
    1. Balar A.V., Galsky M.D., Rosenberg J.E., Powles T., Petrylak D.P., Bellmunt J., Loriot Y., Necchi A., Hoffman-Censits J., Perez-Gracia J.L., et al. Atezolizumab as first-line treatment in cisplatin ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67–76. doi: 10.1016/S0140-6736(16)32455-2.
    1. O’Donnel P., Grivas P., Balar A.V., Bellmunt J., Vuky J., Powles T., Plimack E.R., Hahn N.M., De Wit R., Pang L., et al. Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC); Proceedings of the 2017 ASCO Annual Meeting Genitourinary (Nonprostate) Cancer Oral Abstract Session; Chicago, IL, USA. 2–6 June 2017.
    1. Balar A.V., Castellano D., O’Donnell P.H., Grivas P., Vuky J., Powles T., Plimack E.R., Hahn N.M., de Wit R., Pang L., et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): A multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483–1492. doi: 10.1016/S1470-2045(17)30616-2.
    1. Patel M.R., Ellerton J., Infante J.R., Agrawal M., Gordon M., Aljumaily R., Britten C.D., Dirix L., Lee K.W., Taylor M., et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): Pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19:51–64. doi: 10.1016/S1470-2045(17)30900-2.
    1. Powles T., O’Donnell P.H., Massard C., Arkenau H.T., Friedlander T.W., Hoimes C.J., Lee J.L., Ong M., Sridhar S.S., Vogelzang N.J., et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1/2 open-label study. JAMA Oncol. 2017;3:e172411. doi: 10.1001/jamaoncol.2017.2411.
    1. Sharma P., Retz M., Siefker-Radtke A., Baron A., Necchi A., Bedke J., Plimack E.R., Vaena D., Grimm M.O., Bracarda S., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312–322. doi: 10.1016/S1470-2045(17)30065-7.
    1. Bellmunt J., de Wit R., Vaughn D.J., Fradet Y., Lee J.L., Fong L., Vogelzang N.J., Climent M.A., Petrylak D.P., Choueiri T.K., et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 2017;376:1015–1026. doi: 10.1056/NEJMoa1613683.
    1. Powles T., Gschwend J.E., Loriot Y., Bellmunt J., Geczi L., Vulsteke C., Abdelsalam M., Gafanov R., Bae W.K., Revesz J., et al. Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer. J. Clin. Oncol. 2017;35:e15. doi: 10.1200/JCO.2017.35.15_suppl.TPS4590.
    1. Galsky M.D., Grande E., Davis I.D., Santis M.D., Arija J.A.A., Kikuchi E., Mecke A., Thastrom A.C., Bamias A. IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) J. Clin. Oncol. 2018;36:e15. doi: 10.1200/JCO.2018.36.15_suppl.TPS4589.
    1. Galsky M.D., Necchi A., Sridhar S.S., Ogawa O., Angra N., Hois S., He P., Ghiorghiu D.C., Bellmunt J. A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC) J. Clin. Oncol. 2019;37:e15.
    1. Bellmunt J., Theodore C., Demkov T., Komyakov B., Sengelov L., Daugaard G., Caty A., Carles J., Jagiello-Gruszfeld A., Karyakin O., et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 2009;27:4454–4461. doi: 10.1200/JCO.2008.20.5534.
    1. Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–567. doi: 10.1038/nature14011.
    1. Powles T., Duran I., van der Heijden M.S., Loriot Y., Vogelzang N.J., De Giorgi U., Oudard S., Retz M.M., Castellano D., Bamias A., et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748–757. doi: 10.1016/S0140-6736(17)33297-X.
    1. Balar A.V., Bellmunt J., O’Donnell P.H., Castellano D., Grivas P., Vuky J., Powles T., Plimack E.R., Hahn N.M., de Wit R., et al. Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study. Ann. Oncol. 2016;27 doi: 10.1093/annonc/mdw435.25.
    1. Bellmunt J., De Wit R., Vaughn D.J., Fradet Y., Lee J., Fong L., Vogelzang N.J., Climent M.A., Petrylak D.P., Choueiri T.K., et al. Two-year follow up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC) J. Clin. Oncol. 2018;36:e410. doi: 10.1200/JCO.2018.36.6_suppl.410.
    1. Sharma P., Callahan M.K., Bono P., Kim J., Spiliopoulou P., Calvo E., Pillai R.N., Ott P.A., de Braud F., Morse M., et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17:1590–1598. doi: 10.1016/S1470-2045(16)30496-X.
    1. Massard C., Gordon M.S., Sharma S., Rafii S., Wainberg Z.A., Luke J., Curiel T.J., Colon-Otero G., Hamid O., Sanborn R.E., et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 2016;34:3119–3125. doi: 10.1200/JCO.2016.67.9761.
    1. Marlon Rebelatto A.M., Sabalos C., Walker J., Midha A., Steele K., Robbins P.B., Li X., Shi L., Blake-Haskins J.A., Ibrahim R.A., et al. Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients. J. Clin. Oncol. 2015;33:e8033. doi: 10.1200/jco.2015.33.15_suppl.8033.
    1. Chang C.H., Qiu J., O’Sullivan D., Buck M.D., Noguchi T., Curtis J.D., Chen Q., Gindin M., Gubin M.M., van der Windt G.J., et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162:1229–1241. doi: 10.1016/j.cell.2015.08.016.
    1. Hato S.V., Khong A., de Vries I.J., Lesterhuis W.J. Molecular pathways: The immunogenic effects of platinum-based chemotherapeutics. Clin. Cancer Res. 2014;20:2831–2837. doi: 10.1158/1078-0432.CCR-13-3141.
    1. Galsky M.D., Wang H., Hahn N.M., Twardowski P., Pal S.K., Albany C., Fleming M.T., Starodub A., Hauke R.J., Yu M., et al. Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on outcomes. Eur. Urol. 2018;73:751–759. doi: 10.1016/j.eururo.2017.12.001.
    1. Sharma P., Callahan M.K., Calvo A. Efficacy and safety of nivolumab plus ipilimumab in previously treated metastatic urothelial carcinoma: First results from the phase I/II CheckMate 032 study; Proceedings of the 2016 SITC Annual Meeting, National Harbor; Hyattsville, MD, USA. 9–13 November 2016.
    1. Rosenberg J., Sharma P., De Braud F., Basso U., Calvo E., Bono P., Morse M., Ascierto P.A., Lopez-Martin J.A., Brossart P., et al. Nivolumab(N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032. Ann. Oncol. 2018;29:e32. doi: 10.1093/annonc/mdy424.038.
    1. Galsky M.D., Powles T., Li S., Hennicken D., Sonpavde G. A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC.; CheckMate 901) J. Clin. Oncol. 2018;36:TPS4588. doi: 10.1200/JCO.2018.36.15_suppl.TPS4588.
    1. Powles T., Galsky M.D., Castellano D., Van Der Heijden M.S., Petrylak D.P., Armstrong J., Belli R., Ferro S., Ben. Y., Bellmunt J. A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy(CT) in patients (pts) with unresectable stage IV urothelial bladder cancer (UBC): DANUBE. J. Clin. Oncol. 2016;34:TPS4574. doi: 10.1200/JCO.2016.34.15_suppl.TPS4574.
    1. Motz G.T., Coukos G. The parallel lives of angiogenesis and immunosuppression: Cancer and other tales. Nat. Rev. Immunol. 2011;11:702–711. doi: 10.1038/nri3064.
    1. Petrylak D.P., Arkenau H.-T., Perez-Gracia J.L., Krebs M., Santana- Davila R., Yang J., Rege J., Mi G., Ferry D., Herbst R.S. A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma. J. Clin. Oncol. 2017;35:e349. doi: 10.1200/JCO.2017.35.6_suppl.349.
    1. Herbst R.S., Chau I., Petrylak D.P., Arkenau H.-T., Bendell J.C., Santana-Davila R., Calvo E., Penel N., Martin-Liberal J., Soriano A.O., et al. Activity of ramucirumab (R) with pembrolizumab(P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy. J. Clin. Oncol. 2018;36:e3059. doi: 10.1200/JCO.2018.36.15_suppl.3059.
    1. Petrylak D.P., Tagawa S.T., Kohli M., Eisen A., Canil C., Sridhar S.S., Spira A., Yu E.Y., Burke J.M., Shaffer D., et al. Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: An open-label, three arm, randomized controlled phase II trial. J. Clin. Oncol. 2016;34:1500–1509. doi: 10.1200/JCO.2015.65.0218.
    1. Petrylak D.P., de Wit R., Chi K.N., Drakaki A., Sternberg C.N., Nishiyama H., Castellano D., Hussain S., Fléchon A., Bamias A., et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): A randomised, double-blind, phase 3 trial. Lancet. 2017;390:2266–2277. doi: 10.1016/S0140-6736(17)32365-6.
    1. Apolo A.B., Mortazavi A., Stein M.N., Davarpanah N.N., Nadal R.M., Parnes H.L., Ning Y.M., Francis D.C., Cordes L.M., Berniger M.A., et al. A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors. J. Clin. Oncol. 2017;35:e4562. doi: 10.1200/JCO.2017.35.15_suppl.4562.
    1. US National Library of Medicine A Study of Avelumab in Combination with Axitinib in Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) [(accessed on 19 October 2019)]; Available online: .
    1. Hahn N.M., Stadler W.M., Zon R.T., Waterhouse D., Picus J., Nattam S., Johnson C.S., Perkins S.M., Waddell M.J., Sweeney C.J., et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J. Clin. Oncol. 2011;29:1525–1530. doi: 10.1200/JCO.2010.31.6067.
    1. US National Library of Medicine Gemcitabine Hydrochloride and Cisplatin with or Without Bevacizumab in Treating Patients with Advanced Urinary Tract Cancer. [(accessed on 19 October 2019)]; Available online: .
    1. Yakes F.M., Chen J., Tan J., Yamaguchi K., Shi Y.C., Yu P.W., Qian F., Chu F., Bentzien F., Cancilla B., et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 2011;10:2298–2308. doi: 10.1158/1535-7163.MCT-11-0264.
    1. Maia M.C., Agarwal N., McGregor B.A., Vaishampayan U.N., Choueiri T.K., Green M.C. Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC) J. Clin. Oncol. 2018;36:e5. doi: 10.1200/JCO.2018.36.5_suppl.TPS42.
    1. US National Library of Medicine Apatinib with Pembrolizumab in Previously Treated Advanced Malignancies (APPEASE) [(accessed on 10 October 2019)]; Available online: .
    1. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer. 2012;12:237–251. doi: 10.1038/nrc3237.
    1. Siefker-Radtke A.O., Necchi A., Park S.H., GarcÃa-Donas J., Huddart R.A., Burgess E.F., Fleming M.T., Rezazadeh A., Mellado B., Varlamov S., et al. First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA.; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt) J. Clin. Oncol. 2018;36:e4503. doi: 10.1200/JCO.2018.36.15_suppl.4503.
    1. Gavine P.R., Mooney L., Kilgour E., Thomas A.P., Al-Kadhimi K., Beck S., Rooney C., Coleman T., Baker D., Mellor M.J., et al. AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72:2045–2056. doi: 10.1158/0008-5472.CAN-11-3034.
    1. Joerger M., Cassier P., Penel N., Cathomas R., Richly H., Schostak M. Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression. J. Clin. Oncol. 2018;36:e6. doi: 10.1200/JCO.2018.36.6_suppl.494.
    1. Siefker-Radtke A.O., Currie G., Abella E., Vaena D.A., Kalebasty A.R., Curigliano G., Tupikowski K., Andric Z.G., Lugowska I., Kelly W.K., et al. Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. J. Clin. Oncol. 2019;37:4511. doi: 10.1200/JCO.2019.37.15_suppl.4511.
    1. Morrison K., Challita-Eid P.M., Raitano A., An Z., Yang P., Abad J.D., Liu W., Lortie D.R., Snyder J.T., Capo L., et al. Development of ASG-15ME, a novel antibody-drug conjugate targeting SLITRK6, a new urothelial cancer biomarker. Mol. Cancer Ther. 2016;15:1301–1310. doi: 10.1158/1535-7163.MCT-15-0570.
    1. Petrylak D.P., Heath E., Sonpavde G., George S., Morgans A., Eigl B.J., Picus J., Cheng S., Hotte S.J., Gartner E., et al. Interim analysis of a phase 1 dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC) Ann. Oncol. 2016;27:e780. doi: 10.1093/annonc/mdw373.08.
    1. Petrylak D.P., Perez R., Zhang J., Smith D., Ruether J., Sridhar S.S., Sangha R.S., Lang J.M., Heath E.I., Merchan J.R., et al. A phase I study of enfortumab vedotin (ASG-22CE.; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer. J. Clin. Oncol. 2017;35:e106. doi: 10.1200/JCO.2017.35.15_suppl.106.
    1. Rosenberg J., Sridhar S.S., Zhang J., Smith D., Ruether J., Flaig T., Baranda J.C., Lang J.M., Plimack E.R., Sangha R.S., et al. Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC) J. Clin. Oncol. 2018;36:e4504. doi: 10.1200/JCO.2018.36.15_suppl.4504.
    1. Hoimes C.J., Petrylak D.P., Flaig T.W., Carret A.S., Melhem-Bertrandt A., Rosenberg J.E. EV-103 study: A phase 1b dose-escalation and dose expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer. J. Clin. Oncol. 2018;36:TPS532. doi: 10.1200/JCO.2018.36.6_suppl.TPS532.
    1. Bajorin D.F., Sharma P., Quinn D.I., Plimack E.R. Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+urothelial cancer patients (pts) J. Clin. Oncol. 2016;34:e4513. doi: 10.1200/JCO.2016.34.15_suppl.4513.
    1. US National Library of Medicine Vaccine Therapy with or without Sirolimus in Treating Patients with NY-ESO-1 Expressing Solid tumors. [(accessed on 10 October 2019)]; Available online: .
    1. Derré L., Cesson V., Lucca I., Cerantola Y., Valerio M., Fritschi U., Vlamopoulos Y., Burruni R., Legris A.S., Dartiguenave F., et al. Intravesical Bacillus Calmette Guerin combined with a cancer-vaccine increases local T-cell responses in non-muscle-invasive bladder cancer patients. Clin. Cancer Res. 2017;23:717–725. doi: 10.1158/1078-0432.CCR-16-1189.
    1. Sanford T., Donahue R., Jochems C., Dolan R., Bellfield S., Anderson M., Singer E., Weiss R., Elsamra S., Jang T., et al. Immunologic response to a therapeutic cancer vaccine (PANVAC): Initial results from a randomized phase 2 clinical trial (abstract MP15-10) J. Urol. 2017;197:e174. doi: 10.1016/j.juro.2017.02.495.
    1. Morse M.A., Chapman R., Powderly J., Blackwell K., Keler T., Green J., Riggs R., He L.Z., Ramakrishna V., Vitale L., et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin. Cancer Res. 2011;17:4844–4853. doi: 10.1158/1078-0432.CCR-11-0891.
    1. Sharma P., Bajorin D., Jungbluth A., Herr H., Old L., Gnjatic S. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J. Immunother. 2008;31:849–857. doi: 10.1097/CJI.0b013e3181891574.
    1. Ahmad S., Lam T.B., N’Dow J. Significance of MUC1 in bladder cancer. BJU Int. 2015;115:161–162. doi: 10.1111/bju.12727.
    1. D’Costa J.J., Goldsmith J.C., Wilson J.S., Bryan R.T., Ward D.G. A systematic review of the diagnostic and prognostic value of urinary protein biomarkers in urothelial bladder cancer. Bladder Cancer. 2016;2:301–317. doi: 10.3233/BLC-160054.
    1. US National Library of Medicine A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) [(accessed on 10 October 2019)]; Available online: .
    1. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., Royal R.E., Kammula U., White D.E., Mavroukakis S.A., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005;23:2346–2357. doi: 10.1200/JCO.2005.00.240.
    1. Sherif A., Hasan M.N., Radecka E., Rodriguez A.L., Shabo S., Karlsson M., Schumacher M.C., Martis P., Winqvist O. Pilot study of adoptive immunotherapy with sentinel node- derived Tcells in muscle-invasive urinary bladder cancer. Scand. J. Urol. 2015;49:453–462. doi: 10.3109/21681805.2015.1059880.
    1. Maude S.L., Frey N., Shaw P.A., Aplenc R., Barrett D.M., Bunin N.J., Chew A., Gonzalez V.E., Zheng Z., Lacey S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014;371:1507–1517. doi: 10.1056/NEJMoa1407222.
    1. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011;365:725–733. doi: 10.1056/NEJMoa1103849.
    1. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., Teachey D.T., Chew A., Hauck B., Wright J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013;368:1509–1518. doi: 10.1056/NEJMoa1215134.
    1. Lamers C.H., Sleijfer S., van Steenbergen S., van Elzakker P., van Krimpen B., Groot C., Vulto A., den Bakker M., Oosterwijk E., Debets R., et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered Tcells: Clinical evaluation and management of on-target toxicity. Mol. Ther. 2013;21:904–912. doi: 10.1038/mt.2013.17.
    1. Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 2010;18:843–851. doi: 10.1038/mt.2010.24.
    1. Kitano S., Nakayama T., Yamashita M. Biomarkers for immune checkpoint inhibitors in melanoma. Front. Oncol. 2018;8:e270. doi: 10.3389/fonc.2018.00270.
    1. Balar A.V., Loriot Y., Perez-Gracia J.L., Hoffman-Censits J.H., Petrylak D.P., Van Der Heijden M.S., Ding B., Shen X., Rosenberg J.E. Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210. J. Clin. Oncol. 2018;36:e4523. doi: 10.1200/JCO.2018.36.15_suppl.4523.
    1. Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Lee W., Yuan J., Wong P., Ho T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–128. doi: 10.1126/science.aaa1348.
    1. Le D.T., Durham J.N., Smith K.N., Wang H., Bartlett B.R., Aulakh L.K., Lu S., Kemberling H., Wilt C., Luber B.S., et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–413. doi: 10.1126/science.aan6733.
    1. Havel J.J., Chowell D., Chan T.A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer. 2019;19:133–150. doi: 10.1038/s41568-019-0116-x.
    1. Chan T.A., Yarchoan M., Jaffee E., Swanton C., Quezada S.A., Stenzinger A., Peters S. Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic. Ann. Oncol. 2019;30:44–56. doi: 10.1093/annonc/mdy495.
    1. Urun Y., Leow J.J., Fay A.P., Albiges L., Choueiri T.K., Bellmunt J. ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 2017;120:120–126. doi: 10.1016/j.critrevonc.2017.10.012.
    1. Bellmunt J., Paz-Ares L., Cuello M., Cecere F.L., Albiol S., Guillem V., Gallardo E., Carles J., Mendez P., de la Cruz J.J., et al. Spanish Oncology Genitourinary Group. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann. Oncol. 2007;18:522–528. doi: 10.1093/annonc/mdl435.
    1. Teo M.Y., Bambury R.M., Zabor E.C., Jordan E., Al-Ahmadie H., Boyd M.E., Bouvier N., Mullane S.A., Cha E.K., Roper N., et al. DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin. Cancer Res. 2017;23:3610–3618. doi: 10.1158/1078-0432.CCR-16-2520.
    1. Champiat S., Dercle L., Ammari S., Massard C., Hollebecque A., Postel-Vinay S., Chaput N., Eggermont A., Marabelle A., Soria J.C., et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin. Cancer Res. 2017;23:1920–1928. doi: 10.1158/1078-0432.CCR-16-1741.
    1. Wang Q., Gao J., Wu X. Pseudoprogression and hyperprogression after checkpoint blockade. Int. Immunopharmacol. 2018;58:125–135. doi: 10.1016/j.intimp.2018.03.018.
    1. Soria F., Beleni A.I., D’Andrea D., Resch I., Gust K.M., Gontero P., Shariat S.F. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World J. Urol. 2018;36:1703–1709. doi: 10.1007/s00345-018-2264-0.
    1. Seymour L., Bogaerts J., Perrone A., Ford R., Schwartz L.H., Mandrekar S., Lin N.U., Litière S., Dancey J., Chen A., et al. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:143–152. doi: 10.1016/S1470-2045(17)30074-8.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する